BeyondSpring (BYSI) Provides Third-Quarter 2019 Operational and Financial Results Update

Go back to BeyondSpring (BYSI) Provides Third-Quarter 2019 Operational and Financial Results Update

BeyondSpring Provides Third-Quarter 2019 Operational and Financial Results Update

December 18, 2019 7:00 AM UTC

Preparing to Submit NDA in China for Chemotherapy-Induced Neutropenia (CIN) in Q1 2020

Plinabulins Anti-Cancer and CIN Prevention Mechanism Published in Peer Reviewed Journals

NEW YORK, Dec. 18, 2019 (GLOBE NEWSWIRE) --  BeyondSpring Inc. (the Company or BeyondSpring) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today provided an update on the Companys operations and announced its financial results for the three months ended September 30, 2019.

We are pleased with the progress we are seeing in our clinical programs surrounding our lead compound,... More